Therapeutic targeting of BET bromodomain protein, Brd4, delays cyst growth in ADPKD

Xia Zhou, Lucy X. Fan, Dorien J.M. Peters, Marie Trudel, James E. Bradner, Xiaogang Li

Research output: Contribution to journalArticle

28 Citations (Scopus)

Abstract

In this study, we identified a BET bromodomain (BRD) protein, Brd4, not only as a novel epigenetic regulator of autosomal dominant polycystic kidney disease (ADPKD) but also as a novel client protein of Hsp90. We found that Brd4 was upregulated in Pkd1 mutant mouse renal epithelial cells and tissues. This upregulation of Brd4 appears to result from the chaperone activity of Hsp90 and escape proteasomal degradation. We further identify that Brd4 is an upstream regulator of the expression of c-Myc which has been upregulated in all rodent models of PKD and ADPKD patients with unknown mechanism. Inhibition of Brd4 in Pkd1 mutant renal epithelial cells with JQ1, a selective small-molecular inhibitor of BET BRD protein(s), (1) decreased the levels of c-Myc mRNA and protein; (2) increased the levels of p21 mRNA and protein, which was transcriptionally repressed by c-Myc; (3) decreased the phosphorylation of Rb; and (4) decreased cystic epithelial cell proliferation as shown by inhibition of S-phase entry. Most importantly, treatment with JQ1 strikingly delayed cyst growth and kidney enlargement, and preserved renal function in two early stage genetic mouse strains with Pkd1 mutations. This study not only provides one of the mechanisms of how c-Myc is upregulated in PKD but also suggests that targeting Brd4 with JQ1 may function as a novel epigenetic approach in ADPKD. The unraveled link between Brd4 and Hsp90 in ADPKD may also be a general mechanism for the upregulation of Brd4 in cancer cells and opens up avenues for combination therapies against ADPKD and cancer.

Original languageEnglish (US)
Article numberddv136
Pages (from-to)3982-3993
Number of pages12
JournalHuman Molecular Genetics
Volume24
Issue number14
DOIs
StatePublished - Jul 15 2015
Externally publishedYes

Fingerprint

Autosomal Dominant Polycystic Kidney
Cysts
Kidney
Growth
Epithelial Cells
Proteins
Epigenomics
Up-Regulation
Proto-Oncogene Proteins c-myc
Therapeutics
Messenger RNA
Kidney Neoplasms
S Phase
Rodentia
Epithelium
Phosphorylation
Cell Proliferation
Mutation
Neoplasms

ASJC Scopus subject areas

  • Molecular Biology
  • Genetics
  • Genetics(clinical)

Cite this

Zhou, X., Fan, L. X., Peters, D. J. M., Trudel, M., Bradner, J. E., & Li, X. (2015). Therapeutic targeting of BET bromodomain protein, Brd4, delays cyst growth in ADPKD. Human Molecular Genetics, 24(14), 3982-3993. [ddv136]. https://doi.org/10.1093/hmg/ddv136

Therapeutic targeting of BET bromodomain protein, Brd4, delays cyst growth in ADPKD. / Zhou, Xia; Fan, Lucy X.; Peters, Dorien J.M.; Trudel, Marie; Bradner, James E.; Li, Xiaogang.

In: Human Molecular Genetics, Vol. 24, No. 14, ddv136, 15.07.2015, p. 3982-3993.

Research output: Contribution to journalArticle

Zhou, X, Fan, LX, Peters, DJM, Trudel, M, Bradner, JE & Li, X 2015, 'Therapeutic targeting of BET bromodomain protein, Brd4, delays cyst growth in ADPKD', Human Molecular Genetics, vol. 24, no. 14, ddv136, pp. 3982-3993. https://doi.org/10.1093/hmg/ddv136
Zhou, Xia ; Fan, Lucy X. ; Peters, Dorien J.M. ; Trudel, Marie ; Bradner, James E. ; Li, Xiaogang. / Therapeutic targeting of BET bromodomain protein, Brd4, delays cyst growth in ADPKD. In: Human Molecular Genetics. 2015 ; Vol. 24, No. 14. pp. 3982-3993.
@article{557add90cc1f4b878ad5f49c4b882234,
title = "Therapeutic targeting of BET bromodomain protein, Brd4, delays cyst growth in ADPKD",
abstract = "In this study, we identified a BET bromodomain (BRD) protein, Brd4, not only as a novel epigenetic regulator of autosomal dominant polycystic kidney disease (ADPKD) but also as a novel client protein of Hsp90. We found that Brd4 was upregulated in Pkd1 mutant mouse renal epithelial cells and tissues. This upregulation of Brd4 appears to result from the chaperone activity of Hsp90 and escape proteasomal degradation. We further identify that Brd4 is an upstream regulator of the expression of c-Myc which has been upregulated in all rodent models of PKD and ADPKD patients with unknown mechanism. Inhibition of Brd4 in Pkd1 mutant renal epithelial cells with JQ1, a selective small-molecular inhibitor of BET BRD protein(s), (1) decreased the levels of c-Myc mRNA and protein; (2) increased the levels of p21 mRNA and protein, which was transcriptionally repressed by c-Myc; (3) decreased the phosphorylation of Rb; and (4) decreased cystic epithelial cell proliferation as shown by inhibition of S-phase entry. Most importantly, treatment with JQ1 strikingly delayed cyst growth and kidney enlargement, and preserved renal function in two early stage genetic mouse strains with Pkd1 mutations. This study not only provides one of the mechanisms of how c-Myc is upregulated in PKD but also suggests that targeting Brd4 with JQ1 may function as a novel epigenetic approach in ADPKD. The unraveled link between Brd4 and Hsp90 in ADPKD may also be a general mechanism for the upregulation of Brd4 in cancer cells and opens up avenues for combination therapies against ADPKD and cancer.",
author = "Xia Zhou and Fan, {Lucy X.} and Peters, {Dorien J.M.} and Marie Trudel and Bradner, {James E.} and Xiaogang Li",
year = "2015",
month = "7",
day = "15",
doi = "10.1093/hmg/ddv136",
language = "English (US)",
volume = "24",
pages = "3982--3993",
journal = "Human Molecular Genetics",
issn = "0964-6906",
publisher = "Oxford University Press",
number = "14",

}

TY - JOUR

T1 - Therapeutic targeting of BET bromodomain protein, Brd4, delays cyst growth in ADPKD

AU - Zhou, Xia

AU - Fan, Lucy X.

AU - Peters, Dorien J.M.

AU - Trudel, Marie

AU - Bradner, James E.

AU - Li, Xiaogang

PY - 2015/7/15

Y1 - 2015/7/15

N2 - In this study, we identified a BET bromodomain (BRD) protein, Brd4, not only as a novel epigenetic regulator of autosomal dominant polycystic kidney disease (ADPKD) but also as a novel client protein of Hsp90. We found that Brd4 was upregulated in Pkd1 mutant mouse renal epithelial cells and tissues. This upregulation of Brd4 appears to result from the chaperone activity of Hsp90 and escape proteasomal degradation. We further identify that Brd4 is an upstream regulator of the expression of c-Myc which has been upregulated in all rodent models of PKD and ADPKD patients with unknown mechanism. Inhibition of Brd4 in Pkd1 mutant renal epithelial cells with JQ1, a selective small-molecular inhibitor of BET BRD protein(s), (1) decreased the levels of c-Myc mRNA and protein; (2) increased the levels of p21 mRNA and protein, which was transcriptionally repressed by c-Myc; (3) decreased the phosphorylation of Rb; and (4) decreased cystic epithelial cell proliferation as shown by inhibition of S-phase entry. Most importantly, treatment with JQ1 strikingly delayed cyst growth and kidney enlargement, and preserved renal function in two early stage genetic mouse strains with Pkd1 mutations. This study not only provides one of the mechanisms of how c-Myc is upregulated in PKD but also suggests that targeting Brd4 with JQ1 may function as a novel epigenetic approach in ADPKD. The unraveled link between Brd4 and Hsp90 in ADPKD may also be a general mechanism for the upregulation of Brd4 in cancer cells and opens up avenues for combination therapies against ADPKD and cancer.

AB - In this study, we identified a BET bromodomain (BRD) protein, Brd4, not only as a novel epigenetic regulator of autosomal dominant polycystic kidney disease (ADPKD) but also as a novel client protein of Hsp90. We found that Brd4 was upregulated in Pkd1 mutant mouse renal epithelial cells and tissues. This upregulation of Brd4 appears to result from the chaperone activity of Hsp90 and escape proteasomal degradation. We further identify that Brd4 is an upstream regulator of the expression of c-Myc which has been upregulated in all rodent models of PKD and ADPKD patients with unknown mechanism. Inhibition of Brd4 in Pkd1 mutant renal epithelial cells with JQ1, a selective small-molecular inhibitor of BET BRD protein(s), (1) decreased the levels of c-Myc mRNA and protein; (2) increased the levels of p21 mRNA and protein, which was transcriptionally repressed by c-Myc; (3) decreased the phosphorylation of Rb; and (4) decreased cystic epithelial cell proliferation as shown by inhibition of S-phase entry. Most importantly, treatment with JQ1 strikingly delayed cyst growth and kidney enlargement, and preserved renal function in two early stage genetic mouse strains with Pkd1 mutations. This study not only provides one of the mechanisms of how c-Myc is upregulated in PKD but also suggests that targeting Brd4 with JQ1 may function as a novel epigenetic approach in ADPKD. The unraveled link between Brd4 and Hsp90 in ADPKD may also be a general mechanism for the upregulation of Brd4 in cancer cells and opens up avenues for combination therapies against ADPKD and cancer.

UR - http://www.scopus.com/inward/record.url?scp=84936759340&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84936759340&partnerID=8YFLogxK

U2 - 10.1093/hmg/ddv136

DO - 10.1093/hmg/ddv136

M3 - Article

C2 - 25877301

AN - SCOPUS:84936759340

VL - 24

SP - 3982

EP - 3993

JO - Human Molecular Genetics

JF - Human Molecular Genetics

SN - 0964-6906

IS - 14

M1 - ddv136

ER -